Who Can Prescribe Semaglutide and Tirzepatide at a Med Spa?

Semaglutide and tirzepatide are prescription-only drugs.

FDA's instruction to patients is to obtain a prescription from a doctor and fill it at a state-licensed pharmacy, and that holds at a med spa, a weight-loss clinic or a telehealth service alike.

The label itself does not name the professions that may write that prescription.

Who may prescribe and supervise a GLP-1 at a med spa — a physician, an NP or a PA, and whether the exam happens in person or by telehealth — is set by state law, not by the FDA label.

The weight-management products the labels name are Wegovy (semaglutide), Zepbound (tirzepatide) and, as of 2026, Foundayo (orforglipron).

Ozempic and Mounjaro are the diabetes brands of those two molecules, and using them for weight loss in someone without type 2 diabetes is off-label: that use is not on any current US label for either product.

The products themselves — approvals, results, side effects and prices — are the subject of our medical weight loss guide and the semaglutide guide.

The industry's clearest statement on medical injectables is drug-specific.

The American Med Spa Association's position is that injecting botulinum toxin is the practice of medicine, because a prescription ("legend") drug is being used to affect living tissue — so it must be done by a physician, an independent-practice NP or another licensed professional acting within their scope, under rules that vary by state.

We could not confirm an equivalent AmSpa statement written for GLP-1s; who may give a GLP-1 injection is covered below.

Whether the nurse practitioner at the spa can prescribe semaglutide independently depends on the state.

The American Association of Nurse Practitioners sorts the states into three practice categories: Full Practice, where NPs may evaluate, diagnose and prescribe under the board of nursing alone; Reduced Practice, where a career-long collaborative agreement is required for at least one element of practice; and Restricted Practice, where career-long supervision, delegation or team management is required.

AANP publishes the category for each state, so check yours before relying on an NP-only clinic.

Physician assistants are the third prescriber type in the state-law picture, and the structure around them is state law as well — in California, for example, a PA practices under the supervision of a licensed physician and pursuant to a written practice agreement.

Whichever of these professionals a clinic puts forward, the checks are the same: the name, the license type, and the state that issued the license.

A program that will not supply all three has answered the question in its own way.

A good faith exam is the med spa industry's name for the clinical evaluation that precedes treatment.

AmSpa's description of the standard version: before a first treatment, a physician, PA or advanced practice nurse takes a medical history, performs an appropriate physical exam and creates the treatment order.

A registered nurse may assist with the process, but in AmSpa's description the RN cannot generate the order.

AmSpa suggests repeating the exam when the treatment changes, when your health changes, or at least annually — and the association is explicit that the annual repeat is its rule of thumb, not a statute.

Whether the exam itself can happen by telehealth is a state-by-state question, and the states have answered it differently; the telehealth section below runs through named examples.

For a GLP-1 prescription specifically, we could not confirm any nationally required checklist for what the exam must include.

The concrete floor comes from the labels themselves: certain history questions decide whether the drug can be used at all, and those are the next section's subject.

Labs first, and an honest gap: we could not confirm any nationally required lab panel for starting semaglutide or tirzepatide — no source we checked establishes one.

Any lab panel a program requires is that program's own protocol, so the questions to ask are which tests it includes, who reviews them, and whether the fee covers them.

The screenings the labels themselves spell out are history questions.

Both the Wegovy and Zepbound labels say the drug is contraindicated — it should not be used — with a personal or family history of medullary thyroid carcinoma (MTC), or with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

A history question this decisive is where any screening should start.

Pregnancy has its own label rules.

The Wegovy label says to stop when pregnancy is recognized and to discontinue at least 2 months before a planned pregnancy, because of semaglutide's long half-life; breastfeeding is not recommended while taking Wegovy tablets.

The Zepbound label likewise says the drug should be stopped when pregnancy is recognized.

Birth control belongs on the list for Zepbound patients: the label says tirzepatide may reduce the effectiveness of oral contraceptives and advises switching to a non-oral method, or adding a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.

And the prescriber should ask what else you take.

The labels advise against combining Wegovy or Zepbound with any other GLP-1 receptor agonist or another product containing the same drug — relevant when a weight-loss program is already prescribing for you.

Prescribing and injecting are separate acts with separate rules.

AmSpa's generic description of how med spas delegate injectables: after a physician — or a delegated PA or NP — has examined the patient and issued a treatment order, RNs give the injection with documented training in the procedure, NPs inject with documented training under a collaborative agreement or full practice authority, and in the states that allow it, LPNs, LVNs or medical assistants do as well.

Unlicensed people cannot inject on their own, per AmSpa.

Treat that as the trade association's overview of the common model, not as your state's rule.

State boards differ, and several states bar LPNs and medical assistants from injecting.

In California, the Medical Board's position on botulinum toxin is that physicians may inject it or direct RNs and PAs to inject it under their supervision, and that no unlicensed person — the board names medical assistants — may inject it.

We could not confirm a rule written specifically for who may inject a GLP-1 at a med spa.

What a clinic can answer concretely: which licensed professional would give the injection, whose order it falls under, and what training is documented for that person.

Compounded vials add a second layer to "who handles this." FDA's July 2024 alert describes compounded semaglutide dosing errors, some needing hospitalization: patients drew 5 to 20 times the intended dose from multi-dose vials, and clinicians miscalculated milligram-to-"units" conversions by 5 to 10 times.

In one FDA example, a provider meant to prescribe 0.25 mg (5 units) and prescribed 25 units instead — five times the intended dose — and the patient had severe vomiting.

Semaglutide's half-life of about one week means overdose symptoms may need prolonged observation and treatment.

Start with the federal layer.

The Ryan Haight Act normally requires at least one in-person medical evaluation before a practitioner prescribes a controlled substance — testosterone, for example — by telemedicine; DEA/HHS's fourth temporary extension keeps the COVID-era flexibilities, under which no in-person visit is required, in effect from January 1, 2026 through December 31, 2026.

Semaglutide and tirzepatide carry no DEA schedule in their labels, so that in-person requirement appears not to apply to them — but our research could not confirm that reading in an FDA or DEA document, so treat it as our reading and ask any telehealth service how your state's rules apply.

State law fills the space the labels leave, and the answers differ:

• Maine: Chapter 15 generally requires a physician, PA or APRN to do an in-person clinical interview and physical examination for each med spa or IV patient — telehealth only if sufficient for an informed diagnosis — and says a static internet questionnaire is not an acceptable exam for treatment or prescriptions.
• Missouri: providers may not prescribe based solely on a telemedicine evaluation unless a previously established and ongoing physician-patient relationship exists.
• Virginia: guidance says a practitioner-patient relationship can be set up by telemedicine, but questionnaires alone are not enough — without real-time interaction, no valid relationship exists.
• Arizona: for medical aesthetic treatment, the Board of Nursing's opinion calls for an initial face-to-face examination, and says telemedicine may be used for that initial exam.
• California: prescribing, dispensing or furnishing a prescription drug without an appropriate prior examination and a medical indication is unprofessional conduct — and the statute says the prior exam may be done by telehealth, including a self-screening tool or questionnaire, if the standard of care is met.

The spread is the point: the same national telehealth ad can sit on a compliant program in one state and a non-compliant one in another.

Ask where the prescriber is licensed, which state's rules govern your visit, and what the evaluation consists of.

FDA's consumer red flags for GLP-1 sellers are the quickest screen of any online offer: a compounded drug described as the same as an FDA-approved drug; deep discounts that seem too good to be true; no screening and prescription by a licensed doctor; no doctor available for questions; label spelling errors or wrong pharmacy addresses; or a pharmacy name you suspect is fraudulent.

Job titles travel badly across state lines, and "medical director" is the vaguest of them.

Make the clinic translate the title into names, licenses and documents.

Seven questions do it:

• Who is the prescriber of record for GLP-1 patients — name, credential (MD, DO, NP or PA), and which state issued the license?
• Who performs the good faith exam, and is that person a physician, PA or advanced practice nurse rather than a form?
• If an NP prescribes, which AANP practice category does this state fall in?
• Whose order covers the injection, and what training is documented for the person who gives it?
• Which pharmacy fills the prescription, and is it state-licensed?
• Is the medication brand-name or compounded — and if compounded, what did the prescriber document to justify it for me specifically?
• Who owns the clinic, and who employs the prescriber?

The compounded-medication question has a specific legal hook.

FDA's baseline position is that compounded drugs are not FDA-approved — it does not review them for safety, effectiveness or quality before marketing — and that they belong only with patients whose medical needs an approved drug cannot meet.

Under FDA's rules for 503A pharmacies, a compounded GLP-1 with the same active ingredient in a similar strength and route as the approved drug is treated as an "essentially copy" unless the prescriber determines and documents that a change produces a significant difference for an identified individual patient; FDA restated that position in an April 2026 update.

A program that cannot produce that documentation does not have it.

The ownership question has teeth in at least one state.

The Medical Board of California says it is illegal for a physician to serve as "medical director" of a lay-owned medi-spa: to offer laser and other cosmetic medical services, the business must be a physician-owned medical practice or professional medical corporation with a physician as majority shareholder.

Washington, DC's Board of Medicine Policy 15-02 for facilities performing Level II/III procedures calls for a medical director (a DC-licensed MD or DO) and a clinical director each to be physically present at least 50% of weekly operating hours — guidance rather than a mandate, but a concrete benchmark to ask against.

"Prescriber on site" is not one national standard, and the state rules show the range.

Colorado's Rule 1.17 generally requires the delegating physician to be on the premises; when they are not, the delegatee must follow specific written procedure and emergency protocols, and the physician must be physically in Colorado and able to promptly attend to the patient, or name an in-state covering physician.

Delaware's Board of Medical Licensure requires that physical presence — it calls it direct supervision — when a diagnosis is made or a treatment plan involving prescription medications is started.

Alaska's advisory opinion takes the other approach: the supervising physician, APRN or PA must be available to the nurse in person or through electronic communications during a procedure, and on-site presence is not required.

So the same phrase can describe two different clinics, and only your state's rule decides which is compliant.

Ask which model a clinic operates, then check the answer against what your state requires.

One last check: confirm the prescriber's license with the state board that issued it, before your visit rather than after.

FDA's red-flag list — no screening, no licensed doctor, no one available for questions — is the frame for what it means when a program goes quiet on those details.